Ortho Clinical Diagnostics Holdings plc (OCDX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ortho Clinical Diagnostics Holdings plc (OCDX) trades at $17.63 with AI Score 46/100 (Grade C). Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to clinical laboratories and transfusion medicine communities globally. Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for OCDX: OCDX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OCDX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OCDX: the 1 perspectives are evenly split.
How is this calculated? →Ortho Clinical Diagnostics Holdings plc (OCDX) Healthcare & Pipeline Overview
Ortho Clinical Diagnostics Holdings plc delivers in-vitro diagnostic solutions, including automated instruments and assays, serving clinical laboratories and transfusion medicine globally. With a focus on disease detection and blood compatibility, the company operates in the competitive medical diagnostics sector, facing challenges and opportunities in a changing healthcare landscape.
What Is the Investment Thesis for OCDX?
Ortho Clinical Diagnostics Holdings plc operates in the growing in-vitro diagnostics market, driven by increasing healthcare expenditure and demand for advanced diagnostics. The company's comprehensive product portfolio and global presence provide a solid foundation for future growth. However, negative profit margins of -2.7% and a P/E ratio of -78.83 raise concerns about profitability. Upcoming catalysts include potential new product launches and expansion into emerging markets. Potential risks involve increasing competition and regulatory changes. Investors should carefully consider these factors when evaluating OCDX's long-term investment potential.
Based on FMP financials and quantitative analysis
OCDX Key Highlights
- Ortho Clinical Diagnostics Holdings plc operates in the in-vitro diagnostics market, providing solutions to clinical laboratories and transfusion medicine communities.
- The company's product portfolio includes automated instruments, assays, reagents, and other consumables used for disease detection and monitoring.
- OCDX offers COVID-19 antibody and antigen tests, contributing to the global effort to combat the pandemic.
- The company's immunohematology solutions ensure patient-donor compatibility in blood transfusions.
- Ortho Clinical Diagnostics Holdings plc has a gross margin of 50.7%.
Who Are OCDX's Competitors?
OCDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALPN Alpine Immune Sciences, Inc. | $64.97 | +0.02% | $4.46B | 57 |
| CBAY CymaBay Therapeutics | $32.48 | +0.03% | $3.73B | 59 |
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| NARI Inari Medical, Inc. | $79.97 | +0.00% | $4.68B | 57 |
| OLK Olink Holding AB (publ) | $26.08 | +0.31% | $3.24B | 58 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OCDX's Key Strengths?
- Comprehensive product portfolio
- Global presence and established customer base
- Strong focus on innovation and product development
- Expertise in both clinical chemistry and immunohematology
What Are OCDX's Weaknesses?
- Negative profit margin
- High P/E ratio
- Dependence on consumables revenue
- Exposure to regulatory changes
What Could Drive OCDX Stock Higher?
- Potential new product launches in key therapeutic areas.
- Expansion into emerging markets with high growth potential.
- Strategic partnerships to broaden product offerings and market reach.
What Are the Key Risks for OCDX?
- Increasing competition from established players and new entrants.
- Regulatory changes affecting diagnostic testing procedures.
- Economic downturns impacting healthcare spending and demand for diagnostic services.
- Dependence on key suppliers for critical components and materials.
What Are the Growth Opportunities for OCDX?
- Expansion into Emerging Markets: Ortho Clinical Diagnostics can capitalize on the increasing demand for advanced diagnostics in emerging markets. These regions often have underserved healthcare systems and a growing middle class with greater access to healthcare services. By tailoring its product offerings and establishing strategic partnerships, OCDX can gain a significant foothold in these markets. The global in-vitro diagnostics market is projected to reach $100 billion by 2028, with emerging markets contributing a substantial portion of this growth. Timeline: Ongoing.
- Development of Novel Diagnostic Assays: Investing in research and development to create innovative diagnostic assays can drive future growth. Focusing on areas such as personalized medicine and early disease detection can differentiate OCDX from its competitors. The market for personalized medicine diagnostics is expected to reach $20 billion by 2027. This includes developing more sensitive and specific tests for a range of diseases. Timeline: Ongoing.
- Strategic Acquisitions and Partnerships: Pursuing strategic acquisitions and partnerships can expand OCDX's product portfolio and geographic reach. Acquiring companies with complementary technologies or established market presence can accelerate growth and enhance competitiveness. Collaborating with research institutions and other healthcare providers can facilitate the development and commercialization of new diagnostic solutions. Timeline: Ongoing.
- Increased Focus on Automation and Digitalization: Implementing automation and digitalization solutions in diagnostic processes can improve efficiency, reduce costs, and enhance accuracy. Investing in advanced automation technologies and data analytics can streamline laboratory operations and provide valuable insights for healthcare providers. The market for laboratory automation is projected to reach $9 billion by 2025. Timeline: Ongoing.
- Expansion of Point-of-Care Testing Solutions: Developing and expanding point-of-care testing (POCT) solutions can provide rapid and convenient diagnostic results outside of traditional laboratory settings. POCT devices can be used in clinics, emergency rooms, and even at home, enabling faster diagnosis and treatment decisions. The global POCT market is expected to reach $40 billion by 2027, driven by the increasing demand for decentralized healthcare services. Timeline: Ongoing.
What Opportunities Does OCDX Have?
- Expansion into emerging markets
- Development of novel diagnostic assays
- Strategic acquisitions and partnerships
- Increased focus on automation and digitalization
What Threats Does OCDX Face?
- Intense competition from established players
- Technological obsolescence
- Economic downturns affecting healthcare spending
- Changes in reimbursement policies
What Are OCDX's Competitive Advantages?
- Established brand reputation in the in-vitro diagnostics market.
- Comprehensive product portfolio covering a wide range of diagnostic applications.
- Global presence with a broad customer base.
- Strong focus on innovation and product development.
What Does OCDX Do?
Founded in 1939 and headquartered in Raritan, New Jersey, Ortho Clinical Diagnostics Holdings plc (OCDX) has evolved into a global leader in in-vitro diagnostics. The company provides solutions to clinical laboratories and transfusion medicine communities worldwide. Its comprehensive portfolio includes automated instruments, assays, reagents, and other consumables essential for generating test results. These solutions are critical for clinical chemistry, immunoassay testing, and immunohematology. Ortho Clinical Diagnostics' products are utilized in hospitals, laboratories, clinics, blood banks, and donor centers. OCDX's offerings encompass a wide range of diagnostic applications, including tests for detecting and monitoring disease progression across various therapeutic areas. Notably, the company provides COVID-19 antibody and antigen tests. In immunohematology, OCDX provides instruments and tests for blood typing, ensuring patient-donor compatibility in blood transfusions. They also offer donor screening instruments and tests for blood and plasma screening for infectious diseases. Beyond its core diagnostic products, Ortho Clinical Diagnostics is involved in contract manufacturing and orthocare services. The company's long history in the diagnostics industry has allowed it to build a strong reputation for quality and reliability. Ortho Clinical Diagnostics continues to innovate and adapt to the evolving needs of the healthcare industry, focusing on improving patient outcomes through advanced diagnostic solutions.
What Products and Services Does OCDX Offer?
- Provides in-vitro diagnostics solutions to clinical laboratories.
- Offers solutions to transfusion medicine communities worldwide.
- Develops and manufactures automated instruments for diagnostic testing.
- Produces assays, reagents, and other consumables used in diagnostic processes.
- Offers clinical chemistry and immunoassay instruments and tests.
- Provides immunohematology instruments and tests for blood typing.
- Offers donor screening instruments and tests for blood and plasma screening.
- Involved in contract manufacturing and orthocare services.
How Does OCDX Make Money?
- Develops and sells automated diagnostic instruments.
- Generates revenue from the sale of assays, reagents, and consumables used with its instruments.
- Provides contract manufacturing services to other companies.
- Offers orthocare services, including maintenance and support for its products.
What Industry Does OCDX Operate In?
Ortho Clinical Diagnostics Holdings plc operates within the medical diagnostics and research industry, a sector experiencing growth driven by technological advancements and increasing healthcare expenditure. The industry is characterized by intense competition, with key players focusing on innovation and market expansion. Ortho Clinical Diagnostics competes with companies offering similar in-vitro diagnostic solutions. The company's success depends on its ability to maintain a competitive edge through product innovation, strategic partnerships, and effective market penetration.
Who Are OCDX's Key Customers?
- Hospitals
- Laboratories
- Clinics
- Blood banks
- Donor centers
OCDX Valuation & Market Position
Relative to its peer group, OCDX's quantitative score of 46/100 is below the peer average of 57/100.
ROE 18%Key Financial Metrics
Return on equity for Ortho Clinical Diagnostics Holdings plc stands at 18.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -1.6%, showing how much profit it generates from its asset base. A current ratio of 1.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.3%, the inverse of the P/E and a quick read on earnings relative to price.
OCDX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Market sentiment data being refreshed
- Community discussions being analyzed
Bear Case
- AI analysis temporarily unavailable
- Check back shortly for updated insights
- Risk factors being evaluated
- Market concerns being processed
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
OCDX Latest News
No recent news available for OCDX.
OCDX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OCDX.
Price Targets
Wall Street price target analysis for OCDX.
OCDX MoonshotScore
What does this score mean?
The MoonshotScore rates OCDX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
OCDX Healthcare Stock FAQ
What does Ortho Clinical Diagnostics Holdings plc do?
Ortho Clinical Diagnostics Holdings plc is a global provider of in-vitro diagnostics solutions, serving clinical laboratories and transfusion medicine communities. The company develops, manufactures, and markets a range of automated instruments, assays, reagents, and other consumables used in diagnostic testing. Its products are used to detect and monitor disease progression across various therapeutic areas, including infectious diseases, cardiovascular diseases, and cancer. Additionally, OCDX provides solutions for blood typing and donor screening, ensuring patient-donor compatibility in blood transfusions and screening blood and plasma for infectious diseases. The company operates globally, serving hospitals, laboratories, clinics, blood banks, and donor centers.
What are Ortho Clinical Diagnostics Holdings plc's primary revenue streams in healthcare?
Ortho Clinical Diagnostics Holdings plc generates revenue primarily through the sale of its in-vitro diagnostic products and services. This includes revenue from automated instruments used in clinical laboratories and transfusion medicine, as well as recurring revenue from the sale of assays, reagents, and other consumables required to operate these instruments. Revenue is also derived from contract manufacturing and orthocare services, which provide additional streams of income. Geographically, revenue is generated from sales in North America, Europe, Asia-Pacific, and other regions, with a diverse customer base spanning hospitals, laboratories, clinics, blood banks, and donor centers. The company's revenue streams are diversified across product lines, therapeutic areas, and geographic markets, providing a stable foundation for growth.
How does Ortho Clinical Diagnostics Holdings plc navigate regulatory approval processes?
Ortho Clinical Diagnostics Holdings plc operates in a highly regulated industry, requiring adherence to stringent regulatory standards and approval processes. The company must obtain regulatory approvals from agencies such as the FDA in the United States and the EMA in Europe before commercializing its diagnostic products. This involves submitting comprehensive data demonstrating the safety and efficacy of its products, as well as compliance with manufacturing and quality control standards. Ortho Clinical Diagnostics has a dedicated regulatory affairs team responsible for managing these processes and ensuring compliance with applicable regulations. The company's regulatory track record includes successful approvals for a range of diagnostic products, reflecting its commitment to regulatory compliance and product quality. Ongoing efforts are focused on obtaining approvals for new products and maintaining compliance with evolving regulatory requirements.
What are the key factors to evaluate for OCDX?
Ortho Clinical Diagnostics Holdings plc (OCDX) holds an AI score of 46/100 (low). Not financial advice.
How frequently does OCDX data refresh on this page?
OCDX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OCDX's recent stock price performance?
Ortho Clinical Diagnostics Holdings plc (OCDX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OCDX overvalued or undervalued right now?
Valuing Ortho Clinical Diagnostics Holdings plc (OCDX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OCDX?
Before investing in Ortho Clinical Diagnostics Holdings plc (OCDX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be outdated.
- AI analysis pending may provide further insights.